RT Journal Article
SR Electronic
T1 Boosters protect against SARS-CoV-2 infections in young adults during an Omicron-predominant period
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.08.22272056
DO 10.1101/2022.03.08.22272056
A1 Wan, Jiayue
A1 Cazer, Casey L.
A1 Clarkberg, Marin E.
A1 Henderson, Shane G.
A1 Lee, Scarlett E.
A1 Meredith, Genevive
A1 Osman, Marwan
A1 Shmoys, David B.
A1 Frazier, Peter I.
YR 2022
UL http://medrxiv.org/content/early/2022/03/09/2022.03.08.22272056.abstract
AB Background While booster vaccinations clearly reduce the risk of severe COVID-19 and death, the impact of boosters on SARS-CoV-2 infection has not been fully characterized: doing so requires understanding their impact on asymptomatic and mildly symptomatic infections that often go unreported but nevertheless play an important role in spreading SARS-CoV-2. We sought to estimate the impact of COVID-19 booster doses on SARS-CoV-2 infection in a vaccinated and actively surveilled population of young adults during an Omicron-predominant period.Methods and Findings We implemented a cohort study of young adults in a college environment (Cornell University’s Ithaca campus) from December 5, 2021 through December 31, 2021 when Omicron was deemed the predominant SARS-CoV-2 variant on campus. Participants included 15,102 university students fully vaccinated with an FDA-authorized or approved vaccination (BNT162b2, mRNA-1273, or Ad26.COV2.S) who were enrolled in mandatory at-least-weekly surveillance PCR testing, and having no positive SARS-CoV-2 PCR test within 90 days before the start of the study period. Multivariable logistic regression considering those with full vaccination (a 2-dose series of BNT162b2 or mRNA-1273, or 1 dose of Ad26.COV2.S) with a booster dose versus those without a booster dose. 1,870 SARS-CoV-2 infections were identified in the study population. Controlling for gender, student group membership, full vaccination date and initial vaccine type, our analysis estimates that receiving a booster dose reduces the odds of having a PCR-detected SARS-CoV-2 infection relative to full vaccination by 52% (95% confidence interval [37%, 64%]). This result is robust to the choice of the delay over which a booster dose becomes effective (varied from 1 day to 14 days).Conclusions Boosters are effective, relative to full vaccination, in reducing the odds of SARS-CoV-2 infections in a college student population during a period when Omicron was predominant. Therefore, booster vaccinations for this age group can play an important role in reducing community and institutional transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJW and MO were supported by the Cornell University Office of the Provost. PF was supported by AFOSR FA9550-19-1-0283. SH was supported by NSF CMMI-2035086. DS was supported by NSF DCCF-1740822 and NSF DCCF-1522054. CC was supported by The David and Lucile Packard Foundation 2021-72608.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was completed as a part of Cornell University's institutional COVID-19 Modeling Team's contribution to institutional planning and preparedness, and was thus designated by IRB of Cornell University as exempt from IRB review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data presented in the study are available upon reasonable request to the authors. One may contact Cornell University to request the de-identified, source data necessary to replicate the findings in this study.